Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02472145
Title An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

acute myeloid leukemia

bone marrow cancer

myelodysplastic syndrome

Therapies

Decitabine

Decitabine + Talacotuzumab

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU | BEL

Facility Status City State Zip Country Details
Orange California United States Details
Aurora Colorado United States Details
New Orleans Louisiana United States Details
Detroit Michigan United States Details
Lebanon New Hampshire United States Details
New York New York United States Details
Rochester New York United States Details
Charleston South Carolina United States Details
Nashville Tennessee United States Details
Dallas Texas United States Details
Houston Texas United States Details
Herston Australia Details
Melbourne Australia Details
Perth Australia Details
South Woodville Australia Details
Woolloongabba Australia Details
Antwerp Belgium Details
Hasselt Belgium Details
Leuven Belgium Details
Liege Belgium Details
Mons Belgium Details
Turnhout Belgium Details
Wilrijk Belgium Details
Grenoble Cedex 9 France Details
Lyon Cedex 08 France Details
Marseille France Details
Montpellier France Details
Nantes Cedex 2 France Details
Paris Cedex 10 France Details
Toulouse Cedex 9 France Details
Dresden Germany Details
Düsseldorf Germany Details
Essen Germany Details
Frankfurt/Main Germany Details
Hamburg Germany Details
München Germany Details
Münster Germany Details
Ulm Germany Details
Würzburg Germany Details
Haifa Israel Details
Jerusalem Israel Details
Ramat Gan Israel Details
Tel Aviv Israel Details
Busan Korea, Republic of Details
Daegu Korea, Republic of Details
Hwasun Gun Korea, Republic of Details
Seoul Korea, Republic of Details
Katowice Poland Details
Krakow Poland Details
Lodz Poland Details
Lublin Poland Details
Warszawa Poland Details
Chelyabinsk Russian Federation Details
Dzerzhinsk Russian Federation Details
Ekaterinburg Russian Federation Details
Moscow Russian Federation Details
Nizhny Novgorod Russian Federation Details
Ryazan Russian Federation Details
Samara Russian Federation Details
Badalona, Barcelona Spain Details
Barcelona Spain Details
Madrid Spain Details
Pozuelo De Alarcon, Madrid Spain Details
Salamanca Spain Details
Sevilla Spain Details
Valencia Spain Details
Gothenburg Sweden Details
Stockholm Sweden Details
Uppsala Sweden Details
Örebro Sweden Details
Chiayi Taiwan Details
Taichung City Taiwan Details
Tainan City Taiwan Details
Taipei City Taiwan Details
Ankara Turkey Details
Atakum Turkey Details
Istanbul Turkey Details
Izmir Turkey Details
Bournemouth United Kingdom Details
Cardiff United Kingdom Details
Wolverhampton United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field